Pomegranate flowers (PFs) were reported to possess various biological activities such as antidiabetic, anti-inflammatory and hepatoprotective activities, and using to treat diabetes. Although chemical constituents and pharmacological activities of PFs have been studied, unfortunately, there was no report on the pharmacokinetic profile of PFs in vivo. In this study, a selective high-performance liquid chromatography triple quadrupole tandem mass spectrometry (HPLC–QQQ–MS/MS) method was developed and validated for simultaneous quantification of four compounds (corilagin, ellagic acid, gallic acid and brevifolincarboxylic acid) in rat plasma after oral administration of PFs. The good linearity concentration ranges for the four analytes were from 2.5 to 3000 ng/mL with coefficient value R2 > 0.99 in calibration curves. The intra- and inter-day accuracy of the four analytes was in the range of 85.33–102.50%, with relative standard deviation (RSD) of <14.81%. The stability results showed that accuracy of the four analytes was in the range of 81.88–104.74%, with RSD of <14.86%. The validation method was successfully applied to pharmacokinetic profiles of the four analytes in rats after oral administration of PFs extract. This pharmacokinetic study can provide better understanding to clarify in vivo mechanisms of PFs and may facilitate its further development as therapeutic agent.

中文翻译：

---

HPLC-MS/MS同时定量大鼠血浆中四种化合物及其在石榴花口服后药代动力学研究中的应用

据报道，石榴花（PFs）具有多种生物活性，如抗糖尿病、抗炎和保肝活性，并用于治疗糖尿病。尽管已经研究了 PFs 的化学成分和药理活性，但遗憾的是，没有关于 PFs 在体内的药代动力学特征的报道。在本研究中，开发并验证了一种选择性高效液相色谱三重四极杆串联质谱 (HPLC-QQQ-MS/MS) 方法用于同时定量大鼠体内四种化合物（corilagin、鞣花酸、没食子酸和短叶福林羧酸）口服PFs后的血浆。四种分析物的良好线性浓度范围为 2.5 至 3000 ng/mL，系数值 R2 > 5。0.99 的校准曲线。四种分析物的日内和日间准确度在 85.33-102.50% 的范围内，相对标准偏差 (RSD) 小于 14.81%。稳定性结果表明，四种分析物的准确度在81.88-104.74%之间，RSD<14.86%。该验证方法成功地应用于大鼠口服 PFs 提取物后四种分析物的药代动力学曲线。该药代动力学研究可以更好地理解PFs的体内机制，并可能促进其作为治疗剂的进一步发展。该验证方法成功地应用于大鼠口服 PFs 提取物后四种分析物的药代动力学曲线。该药代动力学研究可以更好地理解PFs的体内机制，并可能促进其作为治疗剂的进一步发展。该验证方法成功地应用于大鼠口服 PFs 提取物后四种分析物的药代动力学曲线。该药代动力学研究可以更好地理解PFs的体内机制，并可能促进其作为治疗剂的进一步发展。